趙琦
下載導師簡歷CV
Section 1: Personal Particulars
趙琦
ZHAO QI
Associate Professor
62722638
qizhao@um.edu.mo
University of Macau
UMAC-Faculty of Health Sciences
https://fhs.um.edu.mo/en/staff/qizhao/
Research Project provided for Macao Youth Scholars Program:
基因工程免疫細胞治療在實體瘤中的應用
Application of gene-engineered immune cell therapy in solid tumors
1001 基础医学
1010 医学技术
Honors and Awards
• Dr. Stanley Ho Medical Development Foundation “Set Sail for New Horizons, Create the Future” Grant, 2023
• Incentive Scheme for Outstanding Academic Staff, University of Macau, 2023
• FHS Best Paper Award 2022, University of Macau, 2022
• Peacock Talent Award , Shenzhen Government, 2014
• Federal Technology Transfer Award, NIH, USA, 2011
Patents
• 基因工程化的NK细胞、其制备方法和用途，专利号：ZL202010703308.8;
• 表达抗CD22嵌合抗原受体和PD-L1阻断蛋白的细胞的制备方法、表达载体及应用，申请号：ZL202010891848.3
• 靶向CD22的强杀伤性嵌合抗原受体和T细胞及其在制备治疗肿瘤的药物中的用途，ZL201610318870.2
• 一种化合物及其制备方法和在抗体药物偶联物制备中的用途，专利号：ZL201710633408.6
• IgG杂合型抗TNF和IL-17A双特异性抗体， PCT/CN2015/099847
• 构建HIV病毒抗体酵母展示库的方法和筛选病毒广谱中和抗体的方法及其应用. CN104725501A
• 一种用于抗体表达的表达框、表达载体、含该载体的宿主细胞及其制备方法和应用，CN104711253A
• 一种通用型重组表达载体及其构建方法和应用. CN103725705A
• Antibodies, compositions, and uses，PCT/US2015/047013
• High affinity anti-GD2 antibodies. US2014/029308
• Human monoclonal antibodies to IGF1,2 with picomolar affinity, PCT/US2012/033128
• An engineering recombinant anti-CEA/CD3/CD28 single-chain tri-specific antibody, US 2009/0117108
Section 2: Research Interests and Grants
The team is interested in the development of antibody-based therapeutics for cancer. The research focuses on engineering of monoclonal antibodies, bispecific antibodies, or chimeric antigen receptors (CARs), the delivery of drugs via the nanoparticles. We are identifying novel human monoclonal antibodies from antibody phage libraries. Monoclonal antibodies are designed to destroy tumor cells by utilizing mechanisms of antibody-dependent cellular cytotoxicity (ADCC) or antibody-drug conjugation (ADC). By using these antibodies as vehicles, bispecific antibodies directed at tumor antigens and human CD3 can engage T cells to lyse tumors. Additionally, all of these antibodies can be reshaped to build CAR to redirect T cells.
20
8
3
1. Manufacturing technology and preclinical studies on TCR mimetic antibodymodified T cells for the treatment of liver cancer (FDCT/0009/2023/RIC), 2024-2026, MOP 3,800,000, PI
2. Multi-year Research Grant from University of Macau (MYRG2022-00143-FHS): Development of an IL-15-dimeric tri-specific antibodies recognizing B7-H3 and CD16, 2023-2024, MOP480,000, PI
3. Multi-year Research Grant from University of Macau (MYRG2019-00069-FHS): Targeting B7-H3 with awakened natural killer cells for therapy of non-small cell lung cancer, 2021-2022, MOP150,000, PI
4. Macao Science and Technology Development Fund（FDCT/0043/2021/A1）: Development of anti-B7-H3 CART and bispecific antibodies against non-small cell lung cancer， 2021-2024年, MOP 2,100,000，PI
5. National Major Science R&D Program 国家重大科研发计划（2019YFA0904400）：Synthetic synthesis of functional immune molecules and their application in tumor immunotherapy功能性免疫分子的人工合成及其在肿瘤免疫治疗中的应用， 2020-2024年，RMB 18,600,000，Co-PI
6. Shenzhen-Hong Kong-Macao Science and Technology Programm深圳市科技计划-深港澳（SGDX2020110309280301），NIR-activated photoacoustic probes monitor changes in tumor-infiltrating lymphocytes in real time in tumor evolution近红外激活型光声探针实时监测肿瘤演化中肿瘤浸润性淋巴细胞的变化，2021-2023，RMB 1,000,000, PI
7. Guangzhou Science and Technology Plan for Foreign Science and Technology Cooperation(广州市科技计划对外科技合作)（201807010004）,2018-2021，Development of targeted regulation of PD-1 to enhance WT1-specific T cell therapy technology for leukemia靶向调控PD-1增强WT1特异性T细胞治疗白血病技术的研发，2018-2021，RMB2,000,000，PI
8. Macao Science and Technology Development Fund（FDCT/15/2018/A1）: Development of potent TCR-minic CAR T cells with multiplex genome editing，2018-2021, MOP1,790,000，PI
9. Macao Science and Technology Development Fund（FDCT/131/2016/A3）: Multi-targeting therapy of T-cell receptor-mimic antibodies recognizing tumor-specific class I MHC-peptide epitopes ，2017-2019, MOP 2,100,000，PI
10. Novo Nordisk-CAS Joint Fund (NNCAS-2013-9): Novel bispecific antibodies for the treatment of autoimmune diseases， 2014-2015, RMB 500,000，PI
11. National Natural Science Foundation of China国家自然科学基金项目（31440041）:In vitro directed evolution of T cell receptor-like antibodies in human germline and their application in T cell therapy人germline中T细胞受体样抗体的体外定向进化及在T细胞治疗中的应用, 2015, RMB 150,000，PI
12. Natural Science Foundation of Guangdong Province广东省自然科学基金（2015A030313741）: Research on novel anti-insulin-like growth factor multifunctional antibodies in the treatment of breast cancer新型抗类胰岛素生长因子多功能抗体治疗乳腺癌的研究, 2015-2018, RMB100,000，PI
13. The Department of Science and Technology of Guangdong Province focuses on national international cooperation广东省科技厅重点国家国际合作（2016A050502034）： Research on insulin-like growth factors as therapeutic targets for tumors类胰岛素生长因子作为肿瘤治疗靶点的研究，2016-2018, RMB500,000，PI
14. Shenzhen overseas high-level talent innovation and entrepreneurship funds深圳市海外高层次人才创新创业资金（KQCX20140520154115029）: Research and development of human-derived antibody drugs for the treatment of malignant tumors in children治疗儿童恶性肿瘤人源抗体药物的研发， 2015-2017，RMB500,000，PI
2. Multi-year Research Grant from University of Macau (MYRG2022-00143-FHS): Development of an IL-15-dimeric tri-specific antibodies recognizing B7-H3 and CD16, 2023-2024, MOP480,000, PI
3. Multi-year Research Grant from University of Macau (MYRG2019-00069-FHS): Targeting B7-H3 with awakened natural killer cells for therapy of non-small cell lung cancer, 2021-2022, MOP150,000, PI
4. Macao Science and Technology Development Fund（FDCT/0043/2021/A1）: Development of anti-B7-H3 CART and bispecific antibodies against non-small cell lung cancer， 2021-2024年, MOP 2,100,000，PI
5. National Major Science R&D Program 国家重大科研发计划（2019YFA0904400）：Synthetic synthesis of functional immune molecules and their application in tumor immunotherapy功能性免疫分子的人工合成及其在肿瘤免疫治疗中的应用， 2020-2024年，RMB 18,600,000，Co-PI
6. Shenzhen-Hong Kong-Macao Science and Technology Programm深圳市科技计划-深港澳（SGDX2020110309280301），NIR-activated photoacoustic probes monitor changes in tumor-infiltrating lymphocytes in real time in tumor evolution近红外激活型光声探针实时监测肿瘤演化中肿瘤浸润性淋巴细胞的变化，2021-2023，RMB 1,000,000, PI
7. Guangzhou Science and Technology Plan for Foreign Science and Technology Cooperation(广州市科技计划对外科技合作)（201807010004）,2018-2021，Development of targeted regulation of PD-1 to enhance WT1-specific T cell therapy technology for leukemia靶向调控PD-1增强WT1特异性T细胞治疗白血病技术的研发，2018-2021，RMB2,000,000，PI
8. Macao Science and Technology Development Fund（FDCT/15/2018/A1）: Development of potent TCR-minic CAR T cells with multiplex genome editing，2018-2021, MOP1,790,000，PI
9. Macao Science and Technology Development Fund（FDCT/131/2016/A3）: Multi-targeting therapy of T-cell receptor-mimic antibodies recognizing tumor-specific class I MHC-peptide epitopes ，2017-2019, MOP 2,100,000，PI
10. Novo Nordisk-CAS Joint Fund (NNCAS-2013-9): Novel bispecific antibodies for the treatment of autoimmune diseases， 2014-2015, RMB 500,000，PI
11. National Natural Science Foundation of China国家自然科学基金项目（31440041）:In vitro directed evolution of T cell receptor-like antibodies in human germline and their application in T cell therapy人germline中T细胞受体样抗体的体外定向进化及在T细胞治疗中的应用, 2015, RMB 150,000，PI
12. Natural Science Foundation of Guangdong Province广东省自然科学基金（2015A030313741）: Research on novel anti-insulin-like growth factor multifunctional antibodies in the treatment of breast cancer新型抗类胰岛素生长因子多功能抗体治疗乳腺癌的研究, 2015-2018, RMB100,000，PI
13. The Department of Science and Technology of Guangdong Province focuses on national international cooperation广东省科技厅重点国家国际合作（2016A050502034）： Research on insulin-like growth factors as therapeutic targets for tumors类胰岛素生长因子作为肿瘤治疗靶点的研究，2016-2018, RMB500,000，PI
14. Shenzhen overseas high-level talent innovation and entrepreneurship funds深圳市海外高层次人才创新创业资金（KQCX20140520154115029）: Research and development of human-derived antibody drugs for the treatment of malignant tumors in children治疗儿童恶性肿瘤人源抗体药物的研发， 2015-2017，RMB500,000，PI